Clinical Trial Update: STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer [Phase 2]

View source ↗

Summary

STREAM-2 is a Phase 2 study evaluating regorafenib as a second-line therapy for advanced RAS-mutant metastatic colorectal cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: RECRUITING